<DOC>
	<DOCNO>NCT00367237</DOCNO>
	<brief_summary>This study undertaken compare efficacy onset action infliximab plus methotrexate ( IFX + MTX ) versus methotrexate alone ( MTX ) methotrexate naïve active psoriatic arthritis patient .</brief_summary>
	<brief_title>Remicade Study Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease ( RESPOND ) ( Study P04422 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>The subject must meet ALL criterion list entry study : Subject must demonstrate willingness participate study comply procedure sign write informed consent . Subject age 18 year , either sex race Diagnosis Psoriatic Arthritis peripheral polyarticular involvement . Patients least one following : Distal Interphalangeal Joints ( DIP ) involvement polyarticular arthritis , absence rheumatoid nodule presence psoriasis arthritis mutilans asymmetric peripheral arthritis Negative rheumatoid factor The disease diagnose least 3 month prior screen . Active disease time screen prior receive baseline study medication ( ) define : 5 swollen joint 5 tender joint one follow three category : Erythrocyte Sedimentation Rate ( ESR ) &gt; = 28 mm/h Creactive protein ( CRP ) &gt; = 15 mg/l Morning stiffness &gt; = 45 min Subjects must confirm practice adequate contraception : Female subject childbearing potential ( include woman less 1 year postmenopausal woman become sexually active study ) must agree use medically accept method contraception surgically sterilize prior screen , receive protocolspecified medication , 6 month stop medication . Acceptable method contraception include condom ( male female ) without spermicidal agent , diaphragm cervical cap spermicide , medically prescribe intrauterine device ( IUD ) , oral injectable hormonal contraceptive , surgical sterilization ( e.g. , hysterectomy tubal ligation ) . Female subject childbearing potential must negative pregnancy test Screening . Subjects must eligible antitumor necrosis factor ( TNF ) treatment accord applicable local guideline . For patient chest Xray skin test result must available baseline . If use Nonsteroidal antiinflammatory drug ( NSAIDs ) corticosteroid i.v. , i.m . i.a. , patient must stable dose four week prior screen ( maximum dose 10mg/day prednisone oral equivalent ) . The screening laboratory test must beet follow criterion : Hemoglobin &gt; = 10 g/dl provide low hemoglobin level due disease anemia chronic inflammation . white blood cell ( WBC ) &gt; = 3500 / μl Neutrophils &gt; = 1500 / μl Platelets &gt; = 100 000/ μl Aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase , gammaglutamyltransferase &lt; = 1.5 x upper limit normal Total bilirubin &lt; = 1 x upper limit normal Serum creatinine &lt; = 1.5 mg/dl Patient must able adhere study visit schedule protocol requirement must give informed consent prior screen procedure . The subject exclude entry study ANY criterion list meet : Subject female pregnant , intend become pregnant study ( within 6 month study completion ) , nurse . Patients inflammatory disease might interfere evaluation psoriatic arthritis . Previous treatment Infliximab . Subjects previously receive MTX discontinue DMARD therapy ( i.e. , sulfasalazine , hydroxychloroquine , leflunomide ) . Patients fibromyalgia syndrome . Use cyclosporine tacrolimus within 4 week prior screen . Use IM , IV , IA corticosteroid within 4 week prior screen . Treatment investigational drug within 3 month prior screen . Previous treatment monoclonal antibody fusion protein . A history know allergy murine protein . History infect joint prosthesis within previous 5 year . Chronic infection . History active tuberculosis require treatment within previous 3 year history opportunistic infection within 2 month , uncontrolled active infection document HIV infection . Also exclude patient evidence latent tuberculosis patient old tuberculosis without documented adequate therapy , treat accord local tuberculosis ( TB ) guideline . Subject clinically significant deviation normal physical examination , chest Xray , electrocardiogram ( ECG ) , investigator 's judgment , may interfere study evaluation affect subject safety . Current sign symptom severe uncontrolled disease , investigator opinion would put patient unacceptable risk . History lymphoproliferative disease , current malignancy history malignancy within 5 year successfully treat basal cell carcinoma squamous cell carcinoma skin . Subject part staff family member staff personnel directly involve study . History drug abuse . Subjects participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>